May 5th, 2021 – Focused on the cell therapy manufacturing bottleneck, Cellares turbocharges plans for ‘shuttle’ tech
May 05, 2021
Endpoints
Related News
-
September 11, 2023Cellares and Lyell to Evaluate Automated Manufacturing of Lyell’s CAR T-Cell Therapy on Cellares’ Cell Shuttle Platform
-
August 28, 2023
Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
-
August 23, 2023
Exclusive: Bloomberg Technology’s Ed Ludlow Interviews Cellares’ CEO and Co-founder, Fabian Gerlinghaus on Company’s Massive $255M Series C Up-Round
